Optimization of Immunosuppressive Therapy for Spinal Grafting of Human Spinal Stem Cells in a Rat Model of ALS

Abstract

Previous rodent studies employing monotherapy or combined immunosuppressive regimens have demonstrated a variable degree of spinal xenograft survival in several spinal neurodegenerative models including spinal ischemia, trauma, or amyotrophic lateral sclerosis (ALS). Accordingly, the characterization of optimal immunosuppressive protocols for the specific neurodegenerative model is critical to ensure reliable assessment of potential long-term therapeutic effects associated with cell replacement. In the present study we characterized the survival of human spinal stem cells when grafted into the lumbar spinal cords of a rodent model of ALS, SOD1 (G93A) male and female rats (60-67 days old). Four different immunosuppressive protocols were studied: i) FK506 (q12h); ii) FK506 (qd) + mycophenolate (PO; q12h, up to 7 days postop); iii) FK506 (qd) + mycophenolate (IP; q12h, up to 7 days postop); and iv) FK506 (qd) + mycophenolate (IP; qd, up to 7 days postop). Three weeks after cell grafting the number of surviving human cells was then systematically assessed. The highest density of grafted cells was seen in animals treated with FK506 (qd) and mycophenolate (IP; qd; an average 915 ± 95 grafted cells per spinal cord section). The majority of hNUMA-positive cells colocalized with doublecortin (DCX) immunoreactivity. DCX-positive neurons showed extensive axodendritic sprouting toward surrounding host neurons. In addition, migrating grafted cells were identified up to 500 µm from the graft. In animals treated with FK506 (q12h), FK506 (qd) + mycophenolate (PO; q12h) or FK506 (qd) + mycophenolate (IP; q12h), 11.8 ± 3.4%, 61.2 ± 7.8%, and 99.4 ± 8.9% [expressed as percent of the FK506 (qd) and mycophenolate (IP; qd)] cell survival was seen, respectively. In contrast to animals treated with a combination of FK506 + mycophenolate, robust CD4/8 immunoreactivity was identified in the vicinity of the injection tract in animals treated with FK506 only. These data suggest that a combined, systemically delivered immunosuppression regimen including FK506 and mycophenolate can significantly improve survival of human spinal stem cells after intraspinal transplantation in SOD1 (G93A) rats.Key words: Amyotrophic lateral sclerosis (ALS); Superoxide dismutase 1 (SOD1); Human spinal stem cells; FK506; Mycophenolate INTRODUCTIONDespite the discovery of several putative mechanisms underlying the onset and progression of ALS, there are no therapeutic strategies that successfully modify disAmyotrophic lateral sclerosis (ALS) is a lethal neuromuscular disease characterized by progressive degeneraease progression or outcome (33). Recently, cell-based therapies have emerged as potential treatments for sevtion of upper and lower motor neurons and corresponding motor and respiratory dysfunction. Approximately eral neurological disorders including ALS (18,28). For example, Xu et al. (34) reported that spinal grafting of 10% of patients have an inherited form of the disease, and of these 20% carry a mutation in the superoxide human spinal stem cells (h...

Human neural stem cell transplantation into the corpus callosum of Alzheimer's mice

“…With regard to immunosuppression, previous studies in our laboratory utilized 3 mg/kg tacrolimus, which is largely based on other rodent species 20. As further dose reduction could potentially mitigate the toxic side‐effects of prolonged immunosuppression, we assessed three dosing regimens.…”

Induced Pluripotent Stem Cell Transplantation Improves Locomotor Recovery in Rat Models of Spinal Cord Injury: a Systematic Review and Meta-Analysis of Randomized Controlled Trials

“…In our metaanalysis, only one publication [27] mentioned the use of triple drug immunosuppression containing Cyclosporine A (10 mg/kg), azathioprine sodium (2 mg/kg), methylprednisolone (2 mg/kg, tapered to 0.5 mg/kg) and methylprednisolone (2 mg/kg, tapered to 0.5 mg/kg) to prevent graft rejection. Generally, it is necessary to use initial combined immunosuppressive therapy in order to achieve consistent cell survival at intervals of 2-2.5 months after grafting [46]. Few publications are included, as a result, we need more studies and evidence to valid this method.…”

Stem Cell Transplantation Strategies for the Restoration of Cognitive Dysfunction Caused by Cranial Radiotherapy

“…Under our experimental conditions, transplanted NSCs did not undergo extensive proliferation, so that dilution of the BrdU label was not problematic. Alternatively, transplanted human stem cells can be distinguished from host cells by immunostaining for human specific markers such as nuclear matrix protein (h-NUC or hNUMA) 9 or human-specific nuclear antigen (HuNu) 2 . Human stem cells could also be labeled with a variety of fluorescent markers to facilitate their identification within the host brain.…”